Atlas Trials

Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks

Clinical trial NCT04410965 · COMPLETED

Trial details

NCT number
NCT04410965
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Multiple Sclerosis
Start date
2020-05-20
Primary completion
2021-07-12
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.